ViroGates is listed on Nasdaq OMX First North in Denmark

Tue Jun 26 2018

ViroGates’ initial public offering of new shares was 141% oversubscribed.
As of June 26, 2018 ViroGates is listed on Nasdaq OMX First North in Denmark.

The Company’s offering of a minimum of 659,341 and a maximum of 824,175 newly issued shares at an offer price of
DKK 91 per share has been fully subscribed.
On that background, the final number of offer shares is 824,175, which will provide the Company with gross proceeds of
DKK 75.0 million.
The proceeds are to be deployed to intensify the continued commercial roll-out of the Company’s products and strengthen its product development, clinical documentation and global patent coverage.

The Company’s shares will be admitted to trading under the symbol “VIRO” (ISIN:DK0061030574) as of 26 June 2018.

More information to be found here; Investor – Announcements


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates